Our Mission

Transforming Lives Through RNA Science

AlterRNA is dedicated to developing next-generation RNA therapeutics that address the underlying genetic causes of disease. Our platform technology enables precise modification of RNA to restore normal protein function.

Precision Medicine

Precisely targeting specific genetic mutations

Innovation

Pioneering novel RNA modification technologies

Patient-Centric

Driven by the needs of patients and their families

Scientific Excellence

Committed to rigorous research and development

$50M+

Funding Raised

100+

Team Members

25+

Publications

10+

Patents Filed

THERAPEUTIC FOCUS

Addressing Critical Unmet Needs

Our pipeline targets rare genetic diseases across multiple therapeutic areas, bringing hope to patients with limited treatment options.

Neurology

Rare genetic neurological disorders

3 Programs

Cardiology

Inherited cardiovascular conditions

2 Programs

Ophthalmology

Genetic retinal diseases

1 Programs

Hematology

Blood and immune disorders

2 Programs

Metabolic

Inherited metabolic diseases

1 Programs
Pipeline

Development Pipeline

AlterRNA is dedicated to developing next-generation RNA therapeutics

ART- 001

Duchenne Muscular Dystrophy

Enrolling
Phase 2d

ART- 002

Retinitis Pigmentosa

Active
Phase 1st

ART- 003

Hemophilia A

On Track
Preclinical
COMMUNITY HUB

Collaborative Knowledge Exchange

Join our secure network of researchers, clinicians, and partners to share insights, discuss methodologies, and advance the field of RNA therapeutics together.

Optimizing LNP formulation for delivery to hepatic tissues

Dr. Sarah Chen

  • Lead Researcher
  • 2h ago
Formulation Delivery System
icon20 icon150

Latest FDA guidance on mRNA vaccine stability requirements

James Wilson

  • Regulatory Affairs
  • 5h ago
Regulatory Compliance
icon20 icon150

Protocol for purifying long RNA transcripts (>5kb)

Maria Garcia

  • Biochemist
  • 2h ago
Purification Methodology
icon20 icon150

Optimizing LNP formulation for delivery to hepatic tissues

Dr. Sarah Chen

  • Lead Researcher
  • 2h ago
Formulation Delivery System
icon20 icon150

Latest FDA guidance on mRNA vaccine stability requirements

James Wilson

  • Regulatory Affairs
  • 5h ago
Regulatory Compliance
icon20 icon150

Protocol for purifying long RNA transcripts (>5kb)

Maria Garcia

  • Biochemist
  • 2h ago
Purification Methodology
icon20 icon150
View All Discussionsicon
Investor Relations

Invest in the Future of Bio-Medicine

AlterRNA offers unique opportunities for investors to fund high-potential therapeutic projects with full transparency and data-backed milestones.

$450M+

Research Funded

12

Clinical Stage Assets

85+

Partner Institutions

2.4X

Yearly Growth

Investor Portal